MedTrace Logo

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 393

Last updated 2026-04-01

No results posted yet for this study

Summary

The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.

Conditions

  • Liver Diseases, Alcoholic

Interventions

DRUG

GSK4532990

GSK4532990 will be administered

DRUG

Placebo

Placebo will be administered

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-27
Primary Completion
2027-08-02
Completion
2028-03-07
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • Denmark
  • France
  • Germany
  • Greece
  • Italy
  • Japan
  • Mexico
  • Poland
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06613698 on ClinicalTrials.gov